Did you know?

We are always looking for dedicated and passionate professionals who want to make a positive difference in the lives of those affected by seizure disorders. Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated …The stock price of Mersana Therapeutics Inc (NASDAQ: MRSN) has surged by 3.92 when compared to previous closing price of 1.53, but the company has seen a 0.63% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-10-31 that CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Mersana …CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody ...CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Find the latest Earnings Report Date for Marinus Pharmaceuticals, Inc. Common Stock (MRNS) at Nasdaq.com.CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Mersana Therapeutics Inc (NASDAQ:MRSN) trade information. Sporting 12.80% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 11/14/23 when the MRSN stock price touched $1.41 or saw a rise of 1.4%.Jun 19, 2023 · For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, please contact: Jeffrey P. Campisi ... Fintel reports that on May 11, 2023, Citigroup maintained coverage of Mersana Therapeutics (NASDAQ:MRSN) with a Buy recommendation.. Analyst Price Forecast Suggests 93.56% Upside. As of May 11 ...MRSN Mersana Therapeutics Inc Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I TrialMersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.31. At the close of trading, the stock’s price was $1.55, to imply an increase of 3.68% or $0.05 in intraday trading. The MRSN share’s 52-week high ...Follow. CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline ...Dec 4, 2023 · Citigroup upgraded its rating of Mersana Therapeutics MRSN to Buy with a price target of $5.00, changing its price target from $1.00 to $5.00. Shares of Mersana Therapeutics are trading up 5.26% ... Nov 7, 2023 · Mersana Therapeutics Inc (NASDAQ:MRSN) released its Q3 2023 financial results on November 7, 2023. The company reported a net loss of $41.6 million for the quarter, compared to a net loss of $59.8 ... Mersana Therapeutics Inc (NASDAQ:MRSN) trade information. Sporting 15.15% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 12/01/23 when the MRSN stock price touched $1.90 or saw a rise of 10.38%.Mersana Therapeutics, Inc. Common Stock (MRSN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSMarinus Pharmaceuticals, Inc. 6.86. +0.10. +1.48%. RADN CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...A high-level overview of Mersana Therapeutics, Inc. (MRSN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Martin Huber. Mersana Therapeutics, Inc., NasdaqGS:MRSN CEO Compensation June 5th 2021 Mersana Therapeutics, Inc.'s Growth Over the past three years, Mersana Therapeutics, Inc. has seen its earnings per share (EPS) grow by 23% per year. MRNS After-Hours Quotes. Data is delayed at least 15 minutes. N

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was in 25 hedge funds' portfolios at the end of March. The all time high for this statistic is 30. Our calculations also showed that MRSN isn't among the ...Największe straty zanotowała spłółka Mersana Therapeutics Inc (NASDAQ: MRSN), która była pod kreską 72,63%, zamykając sesję na poziomie 1,07. W końcówce handlu spółka Yellow Corp (NASDAQ: YELL) straciła 44,12% i zakończyła dzień notowań na poziomie 0,57, a spółka ABVC Biopharma Inc (NASDAQ: ABVC) wzrosła o 41,73% …Nov 17, 2023 · The following insider purchased MRSN shares in the last 24 months: Andrew A F Hack ($9,646,046.46). How much insider buying is happening at Mersana Therapeutics? Insiders have purchased a total of 2,382,282 MRSN shares in the last 24 months for a total of $9,646,046.46 bought. Find the latest Institutional Holdings data for Mersana Therapeutics, Inc. Common Stock (MRSN) at Nasdaq.com.

MRSN (U.S.: Nasdaq) Overview News Mersana Therapeutics Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.78 Market Cap $191.73 M Shares...CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN ), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...CAMBRIDGE, Mass., October 31, 2023 – Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Net loss for the second quarter of 2023 was $54.3 million, or. Possible cause: Real time Mersana Therapeutics (MRSN) stock price quote, stock graph, news & anal.